Figure 6.
Migration and survival of low-dose hUCB-MSCs in the ischemic brain. (a) At 7 days and (b) 28 days after 5 × 105 hUCB-MSC administration, hUCB-MSCs were identified by the staining with human nuclei antibody (hNA, green) and the numbers of hNA-positive cells in the ischemic boundary zone (IBZ) of Ipsi hemisphere are illustrated (n = 5 per treatment group). (c) Data are presented as mean numbers of hNA-positive cells ± SD. Note that the numbers of hNA-positive cells were decreased in animals after intravenous administration compared with animals after intrathecal administration. Intrathecally treated groups showed significant differences from the intravenously treated groups in the IBZ. (d) At seven days after 5 × 105 hUCB-MSC administration, hUCB-MSCs undergoing apoptotic cell death were measured by TUNEL staining. The numbers of hNA-TUNEL double-positive cells in the ipsilateral IBZ are illustrated. (e) Quantitative analysis of hNA-TUNEL double-positive cells in the ipsilateral IBZ. Data from five animals are presented as mean values ± SD. There were significantly more hNA-TUNEL double-positive cells in animals after intravenous administration (analysis of variance; *P < 0.05). Nuclei were counterstained with DAPI (blue). Scale bar = 20 μm.